Results of a Study Comparing Glycated Albumin to Other Glycemic Indices.
Intermediate-term glycemic control metrics fulfill a need for measures beyond A1C. Compare glycated albumin (GA), a 14-day blood glucose measure, with other glycemic indices. 24-week prospective study of assay performance. 8 U.S. clinics. Subjects with type 1 (n=73) and type 2 diabetes (n=77) undergoing changes to improve glycemic control (n=98) or with stable diabetes therapy (n=52). GA, fructosamine, and A1C measured at prespecified intervals. Mean blood glucose (MBG) calculated using weekly self-monitored blood glucose profiles. Primary: Pearson correlation between GA and fructosamine. Secondary: magnitude (Spearman correlation) and direction (Kendall correlation) of change of glycemic indices in the first 3 months after a change in diabetes management. GA was more concordant (60.8%) with changes in MBG than fructosamine (55.5%) or A1C (45.5%). Across all subjects and visits, the GA Pearson correlation with fructosamine was 0.920. Pearson correlations with A1C were 0.655 for GA and 0.515 for fructosamine (P<0.001) and with MBG were 0.590 and 0.454, respectively (P<0.001). At the individual subject level, Pearson correlations with both A1C and MBG were higher for GA than fructosamine in 56% of subjects; only 4% of subjects had higher fructosamine correlations with A1C and MBG. GA had a higher Pearson correlation with A1C and MBG in 82% and 70% of subjects, respectively. Compared to fructosamine, GA correlates significantly better with both short-term MBG and long-term A1C and may be more useful than fructosamine in clinical situations requiring monitoring of intermediate-term glycemic control (NCT02489773).